Author:
Li Shijie,Liu Xuefeng,Chen Xiaonan
Abstract
Abstract
Background
Primary bladder sarcoma (PBS) is a rare malignant tumor of the bladder with a poor prognosis, and its disease course is inadequately understood. Therefore, our study aimed to establish a prognostic model to determine individualized prognosis of patients with PBS.
Patients and Methods
Data of 866 patients with PBS, registered from 1973 to 2015, were extracted from the surveillance, epidemiology, and end result (SEER) database. The patients included were randomly split into a training (n = 608) and a validation set (n = 258). Univariate and multivariate Cox regression analyses were employed to identify the important independent prognostic factors. A nomogram was then established to predict overall survival (OS). Using calibration curves, receiver operating characteristic curves, concordance index (C-index), decision curve analysis (DCA), net reclassification improvement (NRI) and integrated discrimination improvement (IDI), the performance of the nomogram was internally validated. We compared the nomogram with the TNM staging system. The application of the risk stratification system was tested using Kaplan–Meier survival analysis.
Results
Age at diagnosis, T-stage, N-stage, M-stage, and tumor size were identified as independent predictors of OS. C-index of the training cohort were 0.675, 0.670, 0.671 for 1-, 3- and 5-year OS, respectively. And that in the validation cohort were 0.701, 0.684, 0.679, respectively. Calibration curves also showed great prediction accuracy. In comparison with TNM staging system, improved net benefits in DCA, evaluated NRI and IDI were obtained. The risk stratification system can significantly distinguish the patients with different survival risk.
Conclusion
A prognostic nomogram was developed and validated in the present study to predict the prognosis of the PBS patients. It may assist clinicians in evaluating the risk factors of patients and formulating an optimal individualized treatment strategy.
Publisher
Springer Science and Business Media LLC
Subject
Urology,Reproductive Medicine,General Medicine
Reference26 articles.
1. Robinson SP, Farooq A, Laniado M, Motiwala H. The demographic features, clinical outcomes, prognosis and treatment options for patients with sarcomatoid carcinoma of the urinary bladder: a single centre experience. Int Braz J Urol. 2018;44(1):45–52.
2. Guo CC, Majewski T, Zhang L, Yao H, Bondaruk J, Wang Y, et al. Dysregulation of EMT drives the progression to clinically aggressive sarcomatoid bladder cancer. Cell Rep. 2019;27(6):1781–93.
3. Kadouri Y, Ouskri S, El Sayegh H, Benslimane L, Nouini Y. Sarcomatoid carcinoma of the urinary bladder: analysis of five cases and literature review. Pan Afr Med J. 2020;36:369.
4. Dali KM, Kacem A, Ben Rhouma S, Chaker K, Sellami A, Nouira Y. Carcino-sarcoma of the urinary bladder with cartilaginous differentiation: about a case report. Urol Case Rep. 2020;28:101053.
5. Ribeiro JGA. Giant leiomyosarcoma of the urinary bladder. J Clin Diagn Res. 2016;10(5):PD14.